Is it time to abandon clinical breast examination?

Belinda E Kiely and Annabel Goodwin
Med J Aust 2021; 215 (10): . || doi: 10.5694/mja2.51285
Published online: 15 November 2021

Despite limits to its clinical value, the potential benefits for women should not be overlooked

Women with mutations in breast cancer predisposition genes have a very high risk of developing breast cancer and are offered risk‐reducing strategies and intensified surveillance; many are referred to specialist risk management clinics. Because magnetic resonance imaging (MRI) is more sensitive for detecting breast cancer at an early stage than mammography,1 it is part of most high risk breast cancer screening programs, and in Australia is covered by Medicare for women at high risk under 50 years of age.2

  • Belinda E Kiely1,2
  • Annabel Goodwin2

  • 1 NHMRC Clinical Trials Centre, the University of Sydney, Sydney, NSW
  • 2 Concord Repatriation General Hospital, Sydney, NSW


Competing interests:

Belinda Kiely has received honoraria from Roche for sitting on an advisory board (2018, 2019), and Annabel Goodwin has received honoraria from AstraZeneca and Pfizer for sitting on advisory boards (2018, 2019).


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.